Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Genetic Screens02:46

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Parental Perspectives and Experiences with Genetic Testing and Surveillance for Cancer Predisposition in Healthy Young Children.

The Journal of pediatrics·2026
Same author

Germline Whole-Genome Sequencing in Early-Onset Pediatric Solid Tumors Implicates Novel Risk Factors.

JCO precision oncology·2026
Same author

Effects of Elexacaftor/Tezacaftor/Ivacaftor on cough frequency, physical activity patterns, and sleep quality in adolescents and adults with cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2026
Same author

Operationalizing the Wilson-Jungner principles for the genomics era: Consensus recommendations from the International Consortium on Newborn Sequencing.

Genetics in medicine : official journal of the American College of Medical Genetics·2026
Same author

Interpreting Neonatal hyperCKemia Identified Through Duchenne Muscular Dystrophy Newborn Screening: A Predictive Model Based on Maternal, Labor, Delivery and Newborn Factors.

Muscle & nerve·2026
Same author

Increasing Access to Genetic Counselors With Disease-Specific Expertise: Development of a Centralized Cystic Fibrosis Genetic Counseling Telehealth Model.

Pediatric pulmonology·2025

Related Experiment Video

Updated: Jun 12, 2026

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

Cystic fibrosis newborn screening: using experience to optimize the screening algorithm.

Jaime E Hale1, Richard B Parad, Henry L Dorkin

  • 1New England Newborn Screening Program, UMass Medical School, Jamaica Plain, MA 02130, USA.

Journal of Inherited Metabolic Disease
|June 4, 2010
PubMed
Summary

Newborn screening for cystic fibrosis (CF) in Massachusetts has been optimized by analyzing screening data. Key changes include eliminating a screen-positive category and refining risk communication to primary care providers.

More Related Videos

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

Rectal Organoid Morphology Analysis (ROMA): A Diagnostic Assay in Cystic Fibrosis
07:56

Rectal Organoid Morphology Analysis (ROMA): A Diagnostic Assay in Cystic Fibrosis

Published on: June 10, 2022

Related Experiment Videos

Last Updated: Jun 12, 2026

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

Rectal Organoid Morphology Analysis (ROMA): A Diagnostic Assay in Cystic Fibrosis
07:56

Rectal Organoid Morphology Analysis (ROMA): A Diagnostic Assay in Cystic Fibrosis

Published on: June 10, 2022

Area of Science:

  • Biomedical Science
  • Genetics
  • Public Health

Background:

  • Newborn screening (NBS) for cystic fibrosis (CF) has been available in Massachusetts since 1999.
  • Early diagnosis of CF through NBS can improve patient outcomes.
  • An integrated NBS system is ideal for coordinated care and quality improvement.

Purpose of the Study:

  • To analyze Massachusetts's CF NBS data to optimize the screening algorithm.
  • To improve the quality and effectiveness of CF newborn screening.
  • To inform evidence-based decisions for CF NBS program enhancement.

Main Methods:

  • Retrospective analysis of CF NBS data from Massachusetts.
  • Evaluation of the immunoreactive trypsinogen (IRT)-DNA algorithm performance.
  • Assessment of screening outcomes and risk categorization.

Main Results:

  • Decision to eliminate a screen-positive category.
  • Maintenance of the existing IRT cutoff for second-tier DNA testing.
  • Implementation of CF relative risk communication to primary care providers (PCPs).

Conclusions:

  • The CF NBS algorithm in Massachusetts has been refined based on data analysis.
  • Optimized screening and communication strategies aim to improve CF care.
  • The study supports continuous quality improvement in newborn screening programs.